PharmaVoice Mar 31, 2026 mRNA is poised to rise beyond infectious diseases, if it’s not derailed by R&D cuts
PharmaVoice Mar 26, 2026 How former Acorda CEO Ron Cohen landed at a Parkinson’s cell therapy startup
PharmaVoice Mar 16, 2026 340B: When the safest move can feel like no move at all. Why “waiting” is no longer a viable strategy